PharmaCyte Biotech (PMCB) 10-Q 14 Sep 21 2022 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Jul. 31, 2021	Sep. 14, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jul. 31, 2021
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--04-30
Entity File Number	001-40699
Entity Registrant Name	PHARMACYTE BIOTECH, INC.
Entity Central Index Key	0001157075
Entity Tax Identification Number	62-1772151
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	23046 Avenida de la Carlota
Entity Address, Address Line Two	Suite 600
Entity Address, City or Town	Laguna Hills
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92653
City Area Code	(917)
Local Phone Number	595-2850
Title of 12(b) Security	Common Stock, Par Value $0.0001 Per Share
Trading Symbol	PMCB
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		20,715,078

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)	Jul. 31, 2021	Apr. 30, 2021
Current assets:
Cash	$ 959,270	$ 2,202,106
Prepaid expenses and other current assets	549,094	73,131
Total current assets	1,508,364	2,275,237
Other assets:
Intangibles	3,549,427	3,549,427
Investment in SG Austria	1,572,193	1,572,193
Other assets	7,372	7,372
Total other assets	5,128,992	5,128,992
Total Assets	6,637,356	7,404,229
Current liabilities:
Accounts payable	394,775	172,261
Accrued expenses	530,199	552,517
Total current liabilities	924,974	724,778
Total Liabilities	924,974	724,778
Commitments and Contingencies (Notes 7 and 9)
Stockholders' equity:
Common stock, authorized: 33,333,334 shares, $0.0001 par value; 1,611,671 and 1,590,084 shares issued and outstanding as of July 31, 2021 and April 30, 2021, respectively	161	159
Additional paid-in capital	114,169,131	114,109,169
Accumulated deficit	(108,434,913)	(107,409,495)
Accumulated other comprehensive loss	(21,997)	(20,382)
Total stockholders' equity	5,712,382	6,679,451
Total Liabilities and Stockholders' Equity	$ 6,637,356	$ 7,404,229

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares	Jul. 31, 2021	Apr. 30, 2021
Statement of Financial Position [Abstract]
Common stock, authorized	33,333,334	33,333,334
Common stock, par value	$ 0.0001	$ 0.0001
Common stock issued	1,611,671	1,590,084
Common stock, outstanding	1,611,671	1,590,084

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)	3 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Income Statement [Abstract]
Revenue	$ 0	$ 0
Operating expenses:
Research and development costs	143,613	270,574
Compensation expense	268,885	278,970
Director fees	63,159	72,024
Legal and professional	185,748	141,756
General and administrative	361,946	118,352
Total operating expenses	1,023,351	881,676
Loss from operations	(1,023,351)	(881,676)
Other expense:
Interest expense	(467)	(388)
Other expense	(1,600)	(1,880)
Total other expenses	(2,067)	(2,268)
Net loss	$ (1,025,418)	$ (883,944)
Basic and diluted loss per share	$ (0.64)	$ (0.79)
Weighted average shares outstanding basic and diluted	1,591,306	1,119,048

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited) - USD ($)	3 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Income Statement [Abstract]
Net loss	$ (1,025,418)	$ (883,944)
Other comprehensive income (loss):
Foreign currency translation adjustment	(1,615)	2,677
Other comprehensive income (loss)	(1,615)	2,677
Comprehensive loss	$ (1,027,033)	$ (881,267)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Beginning balance, value at Apr. 30, 2020	$ 109	$ 108,968,817	$ (103,858,259)	$ (21,709)	$ 5,088,958
Beginning balance, shares at Apr. 30, 2020	1,092,425
Stock issued for compensation		67,320			67,320
Stock issued for services		40,550			40,550
Stock issued for services, shares	1,667
Stock issued for cash, net of issuance costs of $194,150	$ 16	1,857,381			1,857,397
Stock issued for cash, net of issuance costs of $194,150, shares	156,004
Stock-based compensation options		72,317			72,317
Foreign currency translation adjustment				2,677	2,677
Net loss			(883,944)		(883,944)
Ending balance, value at Jul. 31, 2020	$ 125	111,006,385	(104,742,203)	(19,032)	6,245,275
Ending balance, shares at Jul. 31, 2020	1,250,096
Beginning balance, value at Apr. 30, 2021	$ 159	114,109,169	(107,409,495)	(20,382)	6,679,451
Beginning balance, shares at Apr. 30, 2021	1,590,084
Stock issued for compensation		11,055			11,055
Stock issued for services		24,765			24,765
Stock issued for services, shares	1,336
Stock issued fractions shares -reverse stock split 1 for 1,500	$ 2	(2)
Stock issued fractions shares -reverse stock split 1 for 1,500, shares	20,251
Stock-based compensation options		24,144			24,144
Foreign currency translation adjustment				(1,615)	(1,615)
Net loss			(1,025,418)		(1,025,418)
Ending balance, value at Jul. 31, 2021	$ 161	$ 114,169,131	$ (108,434,913)	$ (21,997)	$ 5,712,382
Ending balance, shares at Jul. 31, 2021	1,611,671

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (Unaudited) (Parenthetical)	3 Months Ended
	Jul. 31, 2020USD ($)
Common Stock [Member]
Payments of Stock Issuance Costs	$ 194,150

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)	3 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Cash flows from operating activities:
Net loss	$ (1,025,418)	$ (883,944)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock issued for services	24,765	40,550
Stock issued for compensation	11,055	67,320
Stock-based compensation – options	24,144	72,317
Change in assets and liabilities:
(Increase) decrease in prepaid expenses and other current assets	(246,930)	6,248
Increase (decrease) in accounts payable	(6,519)	198,990
Decrease in accrued expenses	(22,318)	(52,483)
Net cash used in operating activities	(1,241,221)	(551,002)
Cash flows from investing activities:
Net cash provided by (used in) investing activities	0	0
Cash flows from financing activities:
Use of funds for payment of insurance financing loan	0	(37,337)
Proceeds from sale of common stock, net of issuance costs	0	1,857,397
Net cash provided by financing activities	0	1,820,060
Effect of currency rate exchange on cash	(1,615)	2,677
Net increase (decrease) in cash	(1,242,836)	1,271,735
Cash at beginning of the period	2,202,106	894,861
Cash at end of the period	959,270	2,166,596
Supplemental disclosure of cash flows information:
Cash paid during the periods for income taxes	1,600	800
Cash paid during the periods for interest	467	388
Supplemental information of non-cash activities:
Prepaid expenses included in accounts payable	$ 229,033	$ 0

NATURE OF BUSINESS

NATURE OF BUSINESS	3 Months Ended
	Jul. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF BUSINESS	NOTE 1 – NATURE OF BUSINESS PharmaCyte Biotech, Inc. (“Company”) is a biotechnology company focused on developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box ® ® The Cell-in-a-Box ® The Company is developing therapies for pancreatic and other solid cancerous tumors by using genetically engineered live human cells that we believe are capable of converting a cancer prodrug into its cancer-killing form. The Company encapsulate those cells using the Cell-in-a-Box ® In addition, the Company has been exploring ways to delay the production and accumulation of malignant ascites fluid that results from many types of abdominal cancerous tumors. Malignant ascites fluid is secreted by abdominal cancerous tumors into the abdomen after the tumors have reached a certain stage of growth. This fluid contains cancer cells that can seed and form new tumors throughout the abdomen. This fluid accumulates in the abdominal cavity, causing swelling of the abdomen, severe breathing difficulties and extreme pain. The Company has also been developing a potential therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes. The Company’s product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. The encapsulation will be done using the Cell-in-a-Box ® The Company has also been considering ways to exploit the benefits of the Cell-in-a-Box ® Cannabis Until: (i) the FDA allows the Company to commence a clinical trial in LAPC described in its IND for which the FDA has placed a clinical hold; and (ii) the Company validates its Cell-in-a-Box ® Clinical Hold On September 1, 2020, the Company submitted an IND to the FDA for a planned Phase 2b clinical trial in LAPC. Shortly thereafter, the Company received Information Requests from the FDA related to the IND. The Company timely responded to all information requests. On October 1, 2020, the Company received notice that the FDA had placed the IND on clinical hold. On October 30, 2020, the FDA sent a letter to the Company setting forth the reasons for the clinical hold and specific guidance on what the Company must do to have the clinical hold lifted. In order to lift the clinical hold, the FDA has informed the Company that it needs to conduct several additional preclinical studies. The FDA also requested additional information regarding several topics, including sequencing data, manufacturing information and product release specifications. In addition, the FDA requested that several items not related to the clinical hold be addressed through the submission of an IND amendment. Specifically, the FDA requested that the Company perform qualification studies for the drug substance filling step to ensure that the product remains sterile and stable during the filling process. The FDA also requested additional information, discussion and clarification on several other topics. Since October 30, 2020, there has been no further communication with the FDA regarding the clinical hold. The Company has assembled a scientific team to address the FDA requests related to the clinical hold. That team is working through an extensive list of items that the FDA requested. Among other things, the Company has successfully completed a 9-month product stability study, commenced physical parameter testing for CypCaps™ and commenced additional studies for the sequence of DNA encoding of its encapsulated cells. The Company has also designed the biocompatibility tests for cytotoxicity, sensitization, irritation, acute systemic toxicity, material-mediated pyrogenicity, subacute/subchronic toxicity, genotoxicity and implantation. In addition, the Company has begun a compression and swelling study of CypCaps™, designed a study to determine if CypCaps™ are adversely affected by contrast medium and designed a study to show the catheters used to implant CypCaps™ do not adversely impact the encapsulated cells. Impact of the COVID-19 Pandemic on the Company’s Operations The coronavirus SARS-Cov2 pandemic (“COVID-19”) is causing significant, industry-wide delays in clinical trials. Although the Company is not yet in a clinical trial, the Company has filed an IND with the FDA to commence a clinical trial in LAPC. While the IND has been placed on clinical hold by the FDA, the Company has assessed the impact of COVID-19 on its operations. Currently, many clinical trials are being delayed due to COVID-19. There are numerous reasons for these delays. For example, patients have shown a reluctance to enroll or continue in a clinical trial due to fear of exposure to COVID-19 when they are in a hospital or doctor’s office. There are local, regional and state-wide orders and regulations restricting usual normal activity by people. These discourage and interfere with patient visits to a doctor’s office if the visit is not COVID-19 related. Healthcare providers and health systems are shifting their resources away from clinical trials toward the care of COVID-19 patients. The FDA and other healthcare providers are making product candidates for the treatment of COVID-19 a priority over product candidates unrelated to COVID-19. As of the date of the accompanying condensed consolidated financial statements and related footnotes on Form 10-Q (“Report”), the COVID-19 pandemic has had an impact upon the Company’s operations, although the Company believes that impact is not material. The impact primarily relates to delays in tasks associated with the preparation of the Company’s responses to the clinical hold, including all requested preclinical studies. There may be further delays in generating responses to the requests from the FDA related to the clinical hold. As a result of the COVID-19 pandemic, commencement of the Company’s planned clinical trial to treat LAPC may be delayed beyond the lifting of the clinical hold should that occur. Also, enrollment may be difficult for the reasons discussed above. In addition, after enrollment in the trial, if patients contract COVID-19 during their participation in the trial or are subject to isolation or shelter in place restrictions, this may cause them to drop out of our clinical trial, miss scheduled therapy appointments or follow-up visits or otherwise fail to follow the clinical trial protocol. If patients are unable to follow the clinical trial protocol or if the trial results are otherwise affected by the consequences of the COVID-19 pandemic on patient participation or actions taken to mitigate COVID-19 spread, the integrity of data from the clinical trial may be compromised or not be accepted by the FDA. This could further adversely impact or delay the Company’s clinical development program. It is highly speculative in projecting the effects of COVID-19 on the Company’s clinical development program and the Company generally. The effects of COVID-19 quickly and dramatically change over time. Its evolution is difficult to predict, and no one is able to say with certainty when the pandemic will subside. Company Background The Company is a Nevada corporation incorporated in 1996. In 2013, the Company restructured its operations to focus on biotechnology. The restructuring resulted in the Company focusing all its efforts upon the development of a novel, effective and safe way to treat cancer and diabetes. In January 2015, the Company changed its name from Nuvilex, Inc. to PharmaCyte Biotech, Inc. to reflect the nature of its current business. Increase in Authorized Shares and Reverse Stock Split On July 2, 2021, pursuant to stockholder approval at the Annual Meeting of Stockholders, the Company filed with the Secretary of State of the State of Nevada a Certificate of Amendment to its Articles of Incorporation, as amended, to increase the number of authorized shares to fifty billion ten million (50,010,000,000) shares, of which fifty billion (50,000,000,000) shares, with a par value of $0.0001 per share are designated as common stock and of which ten million (10,000,000) shares, with a par value of $0.0001 per share, are designated as preferred stock. Effective July 12, 2021, pursuant to the approval by the Board of Directors, the Company filed with the Secretary of State of Nevada a Certificate of Change to the Articles of Incorporation, to effect a 1-for-1,500 50,000,000,000 33,333,334 0.0001

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Jul. 31, 2021
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation and Basis of Presentation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. The Company operates independently and through four wholly owned subsidiaries: (i) Bio Blue Bird; (ii) PharmaCyte Biotech Europe Limited; (iii) PharmaCyte Biotech Australia Pty. Ltd.; and (iv) Viridis Biotech, Inc. and are prepared in accordance with U.S. GAAP and the rules and regulations of the Commission. Upon consolidation, intercompany balances and transactions are eliminated. The Company’s 14.5 Use of Estimates in the Preparation of Financial Statements The preparation of financial statements in accordance with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published and the reported amounts of revenues and expenses during the reporting period. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of the Company’s consolidated financial statements; accordingly, it is possible that the actual results could differ from these estimates and assumptions, which could have a material effect on the reported amounts of the Company’s consolidated financial position and results of operations. The severity, magnitude and duration, as well as the economic consequences of the COVID-19 pandemic, are uncertain, rapidly changing and difficult to predict. Therefore, the Company’s accounting estimates and assumptions may change over time in response to the COVID-19 pandemic and may change materially in future periods. Intangible Assets The Financial Accounting Standards Board (“FASB”) standard on goodwill and other intangible assets prescribes a two-step process for impairment testing of goodwill and indefinite-lived intangibles, which is performed annually, as well as when an event triggering impairment may have occurred. The first step tests for impairment, while the second step, if necessary, measures the impairment. The Company has elected to perform its annual analysis at the end of its reporting year. The Company’s intangible assets are licensing agreements related to the Cell-in-a-Box ® 1,549,427 2,000,000 3,549,427 These intangible assets have an indefinite life; therefore, they are not amortizable. The Company concluded that there was no Impairment of Long-Lived Assets The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be fully recoverable. If the estimated future cash flows (undiscounted and without interest charges) from the use of an asset are less than carrying value, a write-down would be recorded to reduce the related asset to its estimated fair value. No impairment was identified or recorded for three months ended July 31, 2021 and 2020. Fair Value of Financial Instruments For certain of the Company’s non-derivative financial instruments, including cash, accounts payable and accrued expenses, the carrying amount approximates fair value due to the short-term maturities of these instruments. Accounting Standards Codification ("ASC") Topic 820, “Fair Value Measurements and Disclosures,” requires disclosure of the fair value of financial instruments held by the Company. ASC Topic 825, “Financial Instruments,” defines fair value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported in the consolidated balance sheets for current liabilities qualify as financial instruments and are a reasonable estimate of their fair values because of the short period between the origination of such instruments and their expected realization and their current market rate of interest. The three levels of valuation hierarchy are defined as follows: • Level 1. Observable inputs such as quoted prices in active markets; • Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and • Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. Income Taxes Deferred taxes are calculated using the liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more-likely-than-not that some portion or all the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. A valuation allowance is provided for deferred income tax assets when, in management’s judgment, based upon currently available information and other factors, it is more likely than not that all or a portion of such deferred income tax assets will not be realized. The determination of the need for a valuation allowance is based on an on-going evaluation of current information including, among other things, historical operating results, estimates of future earnings in different taxing jurisdictions and the expected timing of the reversals of temporary differences. The Company believes the determination to record a valuation allowance to reduce a deferred income tax asset is a significant accounting estimate because it is based on, among other things, an estimate of future taxable income in the U.S. and certain other jurisdictions, which is susceptible to change and may or may not occur, and because the impact of adjusting a valuation allowance may be material. In determining when to release the valuation allowance established against the Company’s net deferred income tax assets, the Company considers all available evidence, both positive and negative. Consistent with the Company’s policy, and because of the Company’s history of operating losses, the Company does not currently recognize the benefit of all its deferred tax assets, including tax loss carry forwards, which may be used to offset future taxable income. The Company continually assesses its ability to generate sufficient taxable income during future periods in which deferred tax assets may be realized. When the Company believes it is more likely than not that it will recover its deferred tax assets, the Company will reverse the valuation allowance as an income tax benefit in the statements of operations. The U.S. GAAP method of accounting for uncertain tax positions utilizes a two-step approach to evaluate tax positions. Step one, recognition, requires evaluation of the tax position to determine if based solely on technical merits it is more likely than not to be sustained upon examination. Step two, measurement, is addressed only if a position is more likely than not to be sustained. In step two, the tax benefit is measured as the largest amount of benefit, determined on a cumulative probability basis, which is more likely than not to be realized upon ultimate settlement with tax authorities. If a position does not meet the more likely than not threshold for recognition in step one, no benefit is recorded until the first subsequent period in which the more likely than not standard is met, the issue is resolved with the taxing authorities or the statute of limitations expires. Positions previously recognized are derecognized when the Company subsequently determines the position no longer is more likely than not to be sustained. Evaluation of tax positions, their technical merits and measurements using cumulative probability are highly subjective management estimates. Actual results could differ materially from these estimates. On March 27, 2020, Congress enacted the Coronavirus Aid, Relief and Economic Security ("CARES") Act to provide certain relief as a result of the Coronavirus Disease 2019 outbreak. The Company maintains a full valuation allowance on its U.S. net deferred tax assets. Deferred tax asset remeasurement (tax expense) was offset by a net decrease in valuation allowance, that resulted in no impact on the Company's income tax expense. Therefore, the Company does not expect the provisions in the CARES Act will impact the Company’s consolidated financial statements. On March 11, 2021, Congress enacted the American Rescue Plan Act of 2021. The Company does not expect the provisions of this act will impact the Company’s consolidated financial statements. Research and Development Research and Development (“R&D”) expenses consist of costs incurred for direct and overhead-related research expenses and are expensed as incurred. Costs to acquire technologies, including licenses, that are utilized in research and development and that have no alternative future use are expensed when incurred. Technology developed for use in the Company’s product candidates is expensed as incurred until technological feasibility has been established. R&D expenses for the three months ended July 31, 2021 and 2020 were $ 143,613 270,574 Stock-Based Compensation The Company recognizes stock-based compensation expense for only those awards ultimately expected to vest on a straight-line basis over the requisite service period of the award. The Company estimates the fair value of stock options using a Black-Scholes-Merton valuation model. This model requires the input of highly subjective assumptions, including the option's expected term and stock price volatility. In addition, judgment is also required in estimating the number of stock-based awards that are expected to be forfeited. Forfeitures are estimated based on historical experience at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The assumptions used in calculating the fair value of share-based payment awards represent management's best estimates, but these estimates involve inherent uncertainties and the application of management's judgment. Thus, if factors change and the Company uses different assumptions, the stock-based compensation expense could be materially different in the future. Concentration of Credit Risk The Company has no significant off-balance-sheet concentrations of credit risk such as foreign exchange contracts, options contracts or other foreign hedging arrangements. The Company maintains most of its cash balance at a financial institution located in California. Accounts at this institution are insured by the Federal Deposit Insurance Corporation up to $250,000. Uninsured balances aggregated approximately $ 679,000 1,921,000 Foreign Currency Translation The Company translates the financial statements of its foreign subsidiaries from the local (functional) currencies to U.S. dollars in accordance with FASB ASC 830, Foreign Currency Matters Liquidity As of July 31, 2021, the Company has an accumulated deficit of $ 108,434,913 1,025,418 On August 9, 2021, the Company entered into an underwriting agreement to offer and sell shares of common stock, pre-funded warrants to purchase common stock and warrants to purchase common stock in a public offering (“First Offering”). The gross proceeds of the First Offering were $ 15 On August 19, 2021, the Company entered into a securities purchase agreement (“Purchase Agreement”) with certain institutional investors (“Purchasers”) pursuant to which the Company agreed to sell in a registered direct offering (“Registered Direct Offering”), shares of the Company’s common stock and pre-funded warrants to purchase shares of common stock. Further, pursuant to the Purchase Agreement, in a concurrent private placement (together with the Registered Direct Offering, “Second Offering”), the Company also agreed to issue to the Purchasers unregistered warrants (“Series A Warrants”) to purchase shares of common stock. The Company received gross proceeds from the Second Offering, before deducting placement agent fees and other estimated offering expenses payable by the Company, of approximately $ 70 The Company believes the cash on hand at July 31, 2021 and the proceeds from the First and Second offerings and warrant exercises provide sufficient capital to meet the Company’s capital requirements through at least one year from the issuance date of these condensed consolidated financial statements. As of September 13, 2021, the Company had cash on hand of approximately $ 88 Recent Accounting Pronouncements ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ASU No. 2019-12, Simplifying the Accounting for Income Taxes In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”) and also issued subsequent amendments to the initial guidance (collectively, “Topic 848”). Topic 848 is effective for all entities as of March 12, 2020 through December 31, 2022 and provides optional guidance for contract modifications and certain hedging relationships associated with the transition from reference rates that are expected to be discontinued. The Company will adopt Topic 848 when relevant contracts are modified upon transition to alternative reference rates. The Company does not expect the adoption of Topic 848 to have a material impact on the Company’s condensed consolidated financial statements.

ACCRUED EXPENSES

ACCRUED EXPENSES	3 Months Ended
	Jul. 31, 2021
Payables and Accruals [Abstract]
ACCRUED EXPENSES	NOTE 3 – ACCRUED EXPENSES Accrued expenses at July 31, 2021 and April 30, 2021 are summarized below: Accrued expenses July 31, 2021 April 30, 2021 Payroll related costs $ 509,793 $ 490,904 Director and Officer insurance 12,786 50,805 Other 7,620 10,808 Total $ 530,199 $ 552,517 The Company financed the Director and Officer insurance policy. The term of the policy is from March 8, 2021 through September 8, 2021 4.85 eight monthly payments 12,829 12,786 50,805

SMALL BUSINESS ADMINISTRATION _

SMALL BUSINESS ADMINISTRATION – PAYCHECK PROTECTION PROGRAM	3 Months Ended
	Jul. 31, 2021
Debt Disclosure [Abstract]
SMALL BUSINESS ADMINISTRATION – PAYCHECK PROTECTION PROGRAM	NOTE 4 – SMALL BUSINESS ADMINISTRATION – PAYCHECK PROTECTION PROGRAM On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted to provide financial aid to family and businesses impacted by the COVID-19 pandemic. The Company participated in the CARES Act, and on April 15, 2020, the Company entered into a note payable with a bank under the Small Business Administration (“SBA”), Paycheck Protection Program (“PPP”) in the amount of $ 75,200 April 15, 2022 1 75,200 779

COMMON STOCK TRANSACTIONS

COMMON STOCK TRANSACTIONS	3 Months Ended
	Jul. 31, 2021
Equity [Abstract]
COMMON STOCK TRANSACTIONS	NOTE 5 – COMMON STOCK TRANSACTIONS A summary of the Company’s compensatory stock activity and related weighted average grant date fair value information for the three months ended July 31, 2021 and 2020 is as follows: During the year ended April 30, 2020, four non-employee members of the Board were issued 1,333 0 7,356 0 In January 2020, the Company awarded 4,400 0 67,320 0 1,833 1,000 3,371 7,029 0 During the three months ended July 31, 2020, four consultants were issued 667 0 4,199 0 500 In September 2020, a consultant was issued 333 2,125 0 0 In January 2021, the Company awarded 4,400 11,055 1,833 During the three months ended July 31, 2021, three non-employee members of the Board were issued 1,002 4,885 0 During the three months ended July 31, 2021, two consultants were issued 334 1,620 251 All shares were issued without registration under the Securities Act in reliance upon the exemption afforded by Section 4(a)(2) of the Securities Act. On September 28, 2017, a S-3 registration statement was declared effective by the Commission for the Company to sell from time to time in one or more public offerings of up to $50 million of its securities on a “shelf offering” basis. During the three months ended July 31, 2021 and 2020, the Company sold and issued approximately 0 156,000 0 1.9 A summary of the Company’s non-vested restricted stock activity and related weighted average grant date fair value information for the three months ended July 31, 2021 are as follows: Schedule of non-vested restricted stock activity Shares Weighted Unvested, at April 30, 2021 2,933 10.05 Granted 1,336 23.96 Vested (2,185 ) 16.66 Forfeited – – Unvested, at July 31, 2021 2,084 12.03

STOCK OPTIONS AND WARRANTS

STOCK OPTIONS AND WARRANTS	3 Months Ended
	Jul. 31, 2021
Share-based Payment Arrangement [Abstract]
STOCK OPTIONS AND WARRANTS	NOTE 6 – STOCK OPTIONS AND WARRANTS Stock Options As of July 31, 2021, the Company had 42,333 During the three months ended July 31, 2021 and 2020, the Company granted 1,000 1,000 The fair value of the Employee Options at the date of grant was estimated using the Black-Scholes-Merton option-pricing model, based on the following weighted average assumptions: Assumptions Three Months Ended July 31, 2021 2020 Risk-free interest rate 0.87 0.3 Expected volatility 113 91 Expected lives (years) 2.5 2.5 Expected dividend yield 0.00 0.00 The Company’s computation of expected volatility is based on the historical daily volatility of its publicly traded stock. For stock option grants issued during the three months ended July 31, 2021 and 2020, the Company used a calculated volatility for each grant. The Company lacks adequate information about the exercise behavior now and has determined the expected term assumption under the simplified method provided for under ASC 718, which averages the contractual term of the Company’s stock options of five years with the average vesting term of two and one-half years for an average of three years. The dividend yield assumption of zero is based upon the fact the Company has never paid cash dividends and presently has no intention of paying cash dividends. The risk-free interest rate used for each grant is equal to the U.S. Treasury rates in effect at the time of the grant for instruments with a similar expected life. During the three months ended July 31, 2021 and 2020, the Company granted no A summary of the Company’s stock option activity and related information for the three months ended July 31, 2021 are shown below: Stock option activity Options Weighted Weighted Outstanding, April 30, 2021 41,333 $ 79.97 $ 79.97 Issued 1,000 23.10 23.10 Forfeited – – – Exercised – – – Outstanding, July 31, 2021 42,333 $ 78.63 $ 78.63 Exercisable, July 31, 2021 39,833 $ 82.93 $ – Vested and expected to vest 42,333 $ 78.63 $ – A summary of the activity for unvested stock options during the years ended April 30, 2021 and 2020 is as follows: Unvested stock option activity Options Weighted Unvested, April 30, 2021 4,000 $ 10.05 Granted 1,000 23.10 Vested (2,500 ) – Forfeited – – Unvested, July 31, 2021 2,500 $ 10.05 The Company recorded $ 24,144 72,317 15,976 five The Company recorded no The following table summarizes the outstanding stock options by exercise price at July 31, 2021: Schedule of options by exercise price Exercise Price Number of Weighted Weighted Number of Weighted Average $ 156.00 6,967 0.39 $ 156.00 6,967 $ 156.00 $ 87.00 1,634 0.69 $ 87.00 1,634 $ 87.00 $ 110.10 800 0.75 $ 110.10 800 $ 110.10 $ 109.35 1,200 0.94 $ 109.35 1,200 $ 109.35 $ 133.50 800 0.96 $ 133.50 800 $ 133.50 $ 82.95 333 0.60 $ 82.95 333 $ 82.95 $ 83.70 6,000 0.85 $ 83.70 6,000 $ 83.70 $ 80.10 800 2.10 $ 80.10 800 $ 80.10 $ 80.85 667 0.88 $ 80.85 667 $ 80.85 $ 102.45 333 0.96 $ 102.45 333 $ 102.45 $ 97.35 333 1.10 $ 97.35 333 $ 97.35 $ 74.25 6,000 1.58 $ 74.25 6,000 $ 74.25 $ 57.00 800 3.15 $ 57.00 800 $ 57.00 $ 60.60 667 1.38 $ 60.60 667 $ 60.60 $ 55.50 333 1.46 $ 55.50 333 $ 55.50 $ 51.00 333 1.6 $ 51.00 333 $ 51.00 $ 61.20 6,000 2.06 $ 61.20 6,000 $ 61.20 $ 36.00 667 1.88 $ 36.00 667 $ 36.00 $ 37.05 333 1.96 $ 37.05 333 $ 37.05 $ 15.75 333 2.10 $ 15.70 333 $ 15.70 $ 10.05 6,000 2.65 $ 10.05 3,500 $ 10.05 $ 26.55 667 2.38 $ 26.55 667 $ 26.55 $ 16.20 333 2.46 $ 16.20 333 $ 16.20 Total 42,333 1.44 $ 78.63 39,833 $ 82.93 The aggregate intrinsic value of outstanding options as of July 31, 2021 was $ 6,860 12.01 Warrants The warrants issued by the Company are equity-classified. The fair value of the warrants was recorded as additional paid-in-capital, and no further adjustments are made. For stock warrants paid in consideration of services rendered by non-employees, the Company recognizes consulting expense in accordance with the requirements of ASC 505. A summary of the Company’s warrant activity and related information for the three months ended July 31, 2021 are shown below: Warrant activity Warrants Weighted Per Share Outstanding, April 30, 2021 2,981 $ 58.70 Issued – – Exercised – – Expired – – Outstanding, July 31, 2021 2,981 – Exercisable, July 31, 2021 2,981 $ 58.70 The following table summarizes additional information concerning warrants outstanding and exercisable at July 31, 2021: Schedule of warrants outstanding and exercisable Exercise Prices Number of Weighted Weighted $97.50 513 0.39 $86.25 580 0.68 $37.50 1,333 0.99 $45.00 555 0.81 2,981 0.79 $ 58.70

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS	3 Months Ended
	Jul. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
LEGAL PROCEEDINGS	NOTE 7 – LEGAL PROCEEDINGS There is no material litigation currently pending against the Company or any of its subsidiaries or to which any of the subsidiaries’ property is subject. To the Company’s knowledge, there is no material litigation against any of its officers or directors in their capacity as such, and no such litigation is contemplated by any governmental authorities.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	3 Months Ended
	Jul. 31, 2021
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 8 – RELATED PARTY TRANSACTIONS The Company had the following related party transactions during the three months ended July 31, 2021 and 2020, respectively. The Company owns 14.5 58,000 64,000 In April 2014, the Company entered a Consulting Agreement with Vin-de-Bona Trading Company, Pte. Ltd. (“Vin-de Bona”) pursuant to which it agreed to provide professional consulting services to the Company. Vin-de-Bona is owned by Prof. Walter H. Günzburg (“Prof. Günzburg”) and Dr. Brian Salmons (“Dr. Salmons”), both of whom are involved in numerous aspects of the Company’s scientific endeavors relating to cancer and diabetes (Prof. Gunzburg is the Chairman of Austrianova, and Dr. Salmons is the Chief Executive Officer and President of Austrianova). The term of the agreement is for 12 months, automatically renewable for successive 12-month terms. After the initial term, either party can terminate the agreement by giving the other party 30 days’ written notice before the effective date of termination. The agreement has been automatically renewed annually. The amounts incurred for the three months ended July 31, 2021 and 2020 were approximately $ 32,000 23,000 0 167 0 8,000

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Jul. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 9 – COMMITMENTS AND CONTINGENCIES The Company acquires assets still in development and enters R&D arrangements with third parties that often require milestone and royalty payments to the third-party contingent upon the occurrence of certain future events linked to the success of the asset in development. Milestone payments may be required, contingent upon the successful achievement of an important point in the development lifecycle of the pharmaceutical product (e.g., approval of the product for marketing by a regulatory agency). If required by the license agreements, the Company may have to make royalty payments based upon a percentage of the sales of the pharmaceutical products if regulatory approval for marketing is obtained. Office Lease In May 2019, the Company entered into a lease for its office space in California for a one-year lease for the leased premises. The term of the lease expired on August 31, 2020. On May 28, 2020, the Company entered into an additional six-month lease of the office space, commencing on September 1, 2020. The term of the new lease expired on February 28, 2021. On May 24, 2021, the Company entered into an additional six-month lease of the office space, commencing on September 1, 2021 which expires on February 28, 2022. Rent expenses for the office for the three months ended July 31, 2021 and 2020 were $ 3,738 7,152 The following table summarizes the Company’s aggregate future minimum lease payments required under the operating lease as of: Schedule of future minimum rental payments for operating leases Period Ending April 30, 2022 Amount $ 8,673 $ 8,673 Compensation Agreements The Company entered into executive compensation agreements with its three executive officers in March 2015, each of which was amended in December 2015 and March 2017. Each agreement has a term of two years with annual extensions thereafter unless the Company or the officer provides written notification of termination at least ninety days prior to the end of the term or subsequent extensions. The Company also entered a compensation agreement with a Board member in April 2015 which continued in effect until amended in May 2017. In May 2017, the Company amended the compensation agreement with the Board members and the terms continue in effect until a member is no longer on the Board. The Company has four independent directors. Each director receives the same compensation: (i) $12,500 in cash for each calendar quarter of service on the Board; (ii) 333 fully paid, non-assessable shares of the Company’s restricted common stock (“Shares”) annually; and (iii) a five-year option to purchase 333 Shares annually at an exercise price equal to the fair market value of the Shares on the date of grant. The Shares and the option Shares fully vest on the date of the grants.

INCOME TAXES

INCOME TAXES	3 Months Ended
	Jul. 31, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 10 - INCOME TAXES The Company had no 295,000 98,000 There was no material difference between the effective tax rate and the projected blended statutory tax rate for the three months ended July 31, 2021 and 2020. Current tax laws limit the amount of loss available to be offset against future taxable income when a substantial change in ownership occurs. Therefore, the amount available to offset future taxable income may be limited. Based on the assessment of all available evidence including, but not limited to, the Company’s limited operating history in its core business and lack of profitability, uncertainties of the commercial viability of its technology, the impact of government regulations and healthcare reform initiatives and other risks normally associated with biotechnology companies, the Company has concluded that is more-likely-than-not that these operating loss carryforwards will not be realized. Accordingly, 100% of the deferred tax valuation allowance has been recorded against these assets at July 31, 2021. The Company’s policy is to recognize any interest and penalties related to unrecognized tax benefits as a component of income tax expense. As of the three months ended July 31, 2021 and 2020, the Company had no See Note 10 of Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended April 30, 2021 for additional information regarding income taxes.

EARNINGS PER SHARE

EARNINGS PER SHARE	3 Months Ended
	Jul. 31, 2021
Earnings Per Share [Abstract]
EARNINGS PER SHARE	NOTE 11 – EARNINGS PER SHARE Basic earnings (loss) per share is computed by dividing earnings available to common stockholders by the weighted average number of shares outstanding during the period. Diluted earnings per share is computed by dividing net income by the weighted average number of shares and potentially dilutive shares of common stock outstanding during the period increased to include the number of additional shares of common stock that would be outstanding if the potentially dilutive securities had been issued. Potential shares of common stock outstanding principally include stock options and warrants. During the periods ended July 31, 2021 and 2020, the Company incurred losses. Accordingly, the effect of any common stock equivalent would be anti-dilutive during those periods and are not included in the calculation of diluted weighted average number of shares outstanding. The table below sets forth the basic loss per share calculations: Earnings per share calculations Three months Ended July 31, 2021 2020 Net loss $ (1,025,418 ) $ (883,944 ) Basic weighted average number of shares outstanding 1,591,306 1,119,048 Diluted weighted average number of shares outstanding 1,591,306 1,119,048 Basic and diluted loss per share $ (0.64 ) $ (0.79 ) The table below sets forth these potentially dilutive securities: Schedule of potentially dilutive securities Three months Ended July 31, 2021 2020 Excluded options 42,333 45,800 Excluded warrants 2,981 39,549 Total excluded options and warrants 45,314 85,349

PREFERRED STOCK

PREFERRED STOCK	3 Months Ended
	Jul. 31, 2021
Equity [Abstract]
PREFERRED STOCK	NOTE 12 – PREFERRED STOCK The Company has authorized 10,000,000 shares of preferred stock, with a par value of $0.0001, of which one share has been designated as "Series A Preferred Stock". The one share of Series A Preferred Stock was issued on October 30, 2019 and repurchased by the Company on December 3, 2019. As of July 31, 2021, there are no shares of preferred stock issued and outstanding. The description of the Series A Preferred Stock below is qualified in its entirety by reference to the Company’s Articles of Incorporation, as amended. The Series A Preferred Stock has the following features: • There is one share of preferred stock designated as Series A Preferred Stock; • The Series A Preferred Stock has a number of votes at any time equal to the number of votes then held by all other shareholders of the Company having a right to vote on any matter plus one. The Certificate of Designations that designated the terms of the Series A Preferred Stock cannot be amended without the consent of the holder of the Series A Preferred Stock; • The Company may redeem the Series A Preferred Stock at any time for a redemption price of $1.00 paid to the holder of the share of Series A Preferred Stock; and • The Series A Preferred Stock has no rights of transfer, conversion, dividends, preferences upon liquidation or participation in any distributions to shareholders.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Jul. 31, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 13 – SUBSEQUENT EVENTS Nasdaq Listing Our common stock began trading on the Nasdaq Capital Market on August 10, 2021, under the symbol “PMCB.” Prior to that, our common stock was quoted on the OTCQB Market under the symbol “PMCB,” and following the reverse stock split of our common stock effective as of July 12, 2021, and until August 6, 2021, the OTCQB Market Symbol for our common stock had temporarily been PMCBD. August 2021 Underwritten Offering On August 9, 2021, the Company entered into an underwriting agreement with H.C. Wainwright & Co. LLC (“Wainwright”) with respect to a public offering of 2,630,385 shares (“Shares”) of common stock, with a par value of $0.0001, 899,027 Pre-funded warrants (“Pre-funded Warrants”) to purchase common stock and common stock warrants (“Common Warrants”) to purchase 3,529,412 shares of common stock. The total gross proceeds of the offering before deduction of underwriting discounts, commissions and estimated offering expenses payable by the Company was approximately $15 million pursuant to the Third S-3. Each share of common stock (or pre-funded warrant in lieu thereof) was sold together with one warrant to purchase one share of common stock at an effective combined public offering price of $4.25 per share of common stock and accompanying warrant, less underwriting discounts and commissions. The Common Warrants have an exercise price of $4.25 per share, are exercisable immediately, and will expire five years following the date of issuance. The Pre-funded Warrants have an exercise price of $0.001 per share, are exercisable immediately, and do not have an expiration date. In addition, the Company granted the Underwriter a 30-day option to purchase up to 529,411 Shares and/or Common Warrants at the public offering price, less underwriting discounts and commissions, which the underwriter has partially exercised for Common Warrants to purchase an aggregate of up to 499,116 shares of common stock. August 2021 Registered Direct Offering and Concurrent Private Placement On August 19, 2021, the Company entered into a Purchase Agreement with certain institutional investors. Pursuant to the Purchase Agreement, the Company agreed to sell in a Registered Direct Offering 8,430,000 shares (“Shares”) of the Company’s Common Stock, with a par value of $0.0001, and Pre-funded warrants to purchase up to 5,570,000 shares of Common Stock. The Pre-Funded Warrants have an exercise price of $0.001 per share and are immediately exercisable and can be exercised at any time after their original issuance until such Pre-Funded Warrants are exercised in full. Each Share was sold at an offering price of $5.00 and each Pre-Funded Warrant was sold at an offering price of $4.999 (equal to the purchase price per Share minus the exercise price of the Pre-Funded Warrant). Pursuant to the Purchase Agreement, in a concurrent private placement (together with the Registered Direct Offering, the “August 19 Offerings”), the Company also agreed to issue to the Purchasers unregistered warrants (“Series A Warrants”) to purchase up to 7,000,000 shares of Common Stock. Each Series A Warrant has an exercise price of $5.00 per share, is exercisable immediately, and will expire five years following the date of issuance. The Company receives gross proceeds from the August 19 Offerings, before deducting placement agent fees and other estimated offering expenses payable by the Company, of approximately $70 million. In addition, the Company issued to Wainwright or its designees upon closing of the August 19 Offerings warrants (“Placement Agent Warrants”) to purchase 1,050,000 shares of common stock at an exercise price of $6.25 per share (which represents 125% of the offering price per Share in the August 19 Offerings). The Placement Agent Warrants will terminate five years after the date of commencement of sales in the Offerings. August 2021 Warrant Exercises As of August 18, 2021, all 899,027 of the Pre-funded Warrants issued in the August 2021 underwritten offering have been exercised. As of August 31, 2021, 2,522,387 of the Common Warrants issued in the August 2021 underwritten offering have been exercised, for aggregate gross proceeds to the Company of $10,720,145. As of August 31, 2021, 4,620,000 of the Pre-funded Warrants issued in the August 19, 2021 Offerings have been exercised, for aggregate gross proceeds to the Company of $4,620.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Jul. 31, 2021
Accounting Policies [Abstract]
Principles of Consolidation and Basis of Presentation	Principles of Consolidation and Basis of Presentation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. The Company operates independently and through four wholly owned subsidiaries: (i) Bio Blue Bird; (ii) PharmaCyte Biotech Europe Limited; (iii) PharmaCyte Biotech Australia Pty. Ltd.; and (iv) Viridis Biotech, Inc. and are prepared in accordance with U.S. GAAP and the rules and regulations of the Commission. Upon consolidation, intercompany balances and transactions are eliminated. The Company’s 14.5
Use of Estimates in the Preparation of Financial Statements	Use of Estimates in the Preparation of Financial Statements The preparation of financial statements in accordance with U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published and the reported amounts of revenues and expenses during the reporting period. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of the Company’s consolidated financial statements; accordingly, it is possible that the actual results could differ from these estimates and assumptions, which could have a material effect on the reported amounts of the Company’s consolidated financial position and results of operations. The severity, magnitude and duration, as well as the economic consequences of the COVID-19 pandemic, are uncertain, rapidly changing and difficult to predict. Therefore, the Company’s accounting estimates and assumptions may change over time in response to the COVID-19 pandemic and may change materially in future periods.
Intangible Assets	Intangible Assets The Financial Accounting Standards Board (“FASB”) standard on goodwill and other intangible assets prescribes a two-step process for impairment testing of goodwill and indefinite-lived intangibles, which is performed annually, as well as when an event triggering impairment may have occurred. The first step tests for impairment, while the second step, if necessary, measures the impairment. The Company has elected to perform its annual analysis at the end of its reporting year. The Company’s intangible assets are licensing agreements related to the Cell-in-a-Box ® 1,549,427 2,000,000 3,549,427 These intangible assets have an indefinite life; therefore, they are not amortizable. The Company concluded that there was no
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be fully recoverable. If the estimated future cash flows (undiscounted and without interest charges) from the use of an asset are less than carrying value, a write-down would be recorded to reduce the related asset to its estimated fair value. No impairment was identified or recorded for three months ended July 31, 2021 and 2020.
Fair Value of Financial Instruments	Fair Value of Financial Instruments For certain of the Company’s non-derivative financial instruments, including cash, accounts payable and accrued expenses, the carrying amount approximates fair value due to the short-term maturities of these instruments. Accounting Standards Codification ("ASC") Topic 820, “Fair Value Measurements and Disclosures,” requires disclosure of the fair value of financial instruments held by the Company. ASC Topic 825, “Financial Instruments,” defines fair value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported in the consolidated balance sheets for current liabilities qualify as financial instruments and are a reasonable estimate of their fair values because of the short period between the origination of such instruments and their expected realization and their current market rate of interest. The three levels of valuation hierarchy are defined as follows: • Level 1. Observable inputs such as quoted prices in active markets; • Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and • Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
Income Taxes	Income Taxes Deferred taxes are calculated using the liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more-likely-than-not that some portion or all the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. A valuation allowance is provided for deferred income tax assets when, in management’s judgment, based upon currently available information and other factors, it is more likely than not that all or a portion of such deferred income tax assets will not be realized. The determination of the need for a valuation allowance is based on an on-going evaluation of current information including, among other things, historical operating results, estimates of future earnings in different taxing jurisdictions and the expected timing of the reversals of temporary differences. The Company believes the determination to record a valuation allowance to reduce a deferred income tax asset is a significant accounting estimate because it is based on, among other things, an estimate of future taxable income in the U.S. and certain other jurisdictions, which is susceptible to change and may or may not occur, and because the impact of adjusting a valuation allowance may be material. In determining when to release the valuation allowance established against the Company’s net deferred income tax assets, the Company considers all available evidence, both positive and negative. Consistent with the Company’s policy, and because of the Company’s history of operating losses, the Company does not currently recognize the benefit of all its deferred tax assets, including tax loss carry forwards, which may be used to offset future taxable income. The Company continually assesses its ability to generate sufficient taxable income during future periods in which deferred tax assets may be realized. When the Company believes it is more likely than not that it will recover its deferred tax assets, the Company will reverse the valuation allowance as an income tax benefit in the statements of operations. The U.S. GAAP method of accounting for uncertain tax positions utilizes a two-step approach to evaluate tax positions. Step one, recognition, requires evaluation of the tax position to determine if based solely on technical merits it is more likely than not to be sustained upon examination. Step two, measurement, is addressed only if a position is more likely than not to be sustained. In step two, the tax benefit is measured as the largest amount of benefit, determined on a cumulative probability basis, which is more likely than not to be realized upon ultimate settlement with tax authorities. If a position does not meet the more likely than not threshold for recognition in step one, no benefit is recorded until the first subsequent period in which the more likely than not standard is met, the issue is resolved with the taxing authorities or the statute of limitations expires. Positions previously recognized are derecognized when the Company subsequently determines the position no longer is more likely than not to be sustained. Evaluation of tax positions, their technical merits and measurements using cumulative probability are highly subjective management estimates. Actual results could differ materially from these estimates. On March 27, 2020, Congress enacted the Coronavirus Aid, Relief and Economic Security ("CARES") Act to provide certain relief as a result of the Coronavirus Disease 2019 outbreak. The Company maintains a full valuation allowance on its U.S. net deferred tax assets. Deferred tax asset remeasurement (tax expense) was offset by a net decrease in valuation allowance, that resulted in no impact on the Company's income tax expense. Therefore, the Company does not expect the provisions in the CARES Act will impact the Company’s consolidated financial statements. On March 11, 2021, Congress enacted the American Rescue Plan Act of 2021. The Company does not expect the provisions of this act will impact the Company’s consolidated financial statements.
Research and Development	Research and Development Research and Development (“R&D”) expenses consist of costs incurred for direct and overhead-related research expenses and are expensed as incurred. Costs to acquire technologies, including licenses, that are utilized in research and development and that have no alternative future use are expensed when incurred. Technology developed for use in the Company’s product candidates is expensed as incurred until technological feasibility has been established. R&D expenses for the three months ended July 31, 2021 and 2020 were $ 143,613 270,574
Stock-Based Compensation	Stock-Based Compensation The Company recognizes stock-based compensation expense for only those awards ultimately expected to vest on a straight-line basis over the requisite service period of the award. The Company estimates the fair value of stock options using a Black-Scholes-Merton valuation model. This model requires the input of highly subjective assumptions, including the option's expected term and stock price volatility. In addition, judgment is also required in estimating the number of stock-based awards that are expected to be forfeited. Forfeitures are estimated based on historical experience at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The assumptions used in calculating the fair value of share-based payment awards represent management's best estimates, but these estimates involve inherent uncertainties and the application of management's judgment. Thus, if factors change and the Company uses different assumptions, the stock-based compensation expense could be materially different in the future.
Concentration of Credit Risk	Concentration of Credit Risk The Company has no significant off-balance-sheet concentrations of credit risk such as foreign exchange contracts, options contracts or other foreign hedging arrangements. The Company maintains most of its cash balance at a financial institution located in California. Accounts at this institution are insured by the Federal Deposit Insurance Corporation up to $250,000. Uninsured balances aggregated approximately $ 679,000 1,921,000
Foreign Currency Translation	Foreign Currency Translation The Company translates the financial statements of its foreign subsidiaries from the local (functional) currencies to U.S. dollars in accordance with FASB ASC 830, Foreign Currency Matters
Liquidity	Liquidity As of July 31, 2021, the Company has an accumulated deficit of $ 108,434,913 1,025,418 On August 9, 2021, the Company entered into an underwriting agreement to offer and sell shares of common stock, pre-funded warrants to purchase common stock and warrants to purchase common stock in a public offering (“First Offering”). The gross proceeds of the First Offering were $ 15 On August 19, 2021, the Company entered into a securities purchase agreement (“Purchase Agreement”) with certain institutional investors (“Purchasers”) pursuant to which the Company agreed to sell in a registered direct offering (“Registered Direct Offering”), shares of the Company’s common stock and pre-funded warrants to purchase shares of common stock. Further, pursuant to the Purchase Agreement, in a concurrent private placement (together with the Registered Direct Offering, “Second Offering”), the Company also agreed to issue to the Purchasers unregistered warrants (“Series A Warrants”) to purchase shares of common stock. The Company received gross proceeds from the Second Offering, before deducting placement agent fees and other estimated offering expenses payable by the Company, of approximately $ 70 The Company believes the cash on hand at July 31, 2021 and the proceeds from the First and Second offerings and warrant exercises provide sufficient capital to meet the Company’s capital requirements through at least one year from the issuance date of these condensed consolidated financial statements. As of September 13, 2021, the Company had cash on hand of approximately $ 88
Recent Accounting Pronouncements	Recent Accounting Pronouncements ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments ASU No. 2019-12, Simplifying the Accounting for Income Taxes In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”) and also issued subsequent amendments to the initial guidance (collectively, “Topic 848”). Topic 848 is effective for all entities as of March 12, 2020 through December 31, 2022 and provides optional guidance for contract modifications and certain hedging relationships associated with the transition from reference rates that are expected to be discontinued. The Company will adopt Topic 848 when relevant contracts are modified upon transition to alternative reference rates. The Company does not expect the adoption of Topic 848 to have a material impact on the Company’s condensed consolidated financial statements.

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	3 Months Ended
	Jul. 31, 2021
Payables and Accruals [Abstract]
Accrued expenses	Accrued expenses July 31, 2021 April 30, 2021 Payroll related costs $ 509,793 $ 490,904 Director and Officer insurance 12,786 50,805 Other 7,620 10,808 Total $ 530,199 $ 552,517

COMMON STOCK TRANSACTIONS (Tabl

COMMON STOCK TRANSACTIONS (Tables)	3 Months Ended
	Jul. 31, 2021
Equity [Abstract]
Schedule of non-vested restricted stock activity	Schedule of non-vested restricted stock activity Shares Weighted Unvested, at April 30, 2021 2,933 10.05 Granted 1,336 23.96 Vested (2,185 ) 16.66 Forfeited – – Unvested, at July 31, 2021 2,084 12.03

STOCK OPTIONS AND WARRANTS (Tab

STOCK OPTIONS AND WARRANTS (Tables)	3 Months Ended
	Jul. 31, 2021
Share-based Payment Arrangement [Abstract]
Assumptions	Assumptions Three Months Ended July 31, 2021 2020 Risk-free interest rate 0.87 0.3 Expected volatility 113 91 Expected lives (years) 2.5 2.5 Expected dividend yield 0.00 0.00
Stock option activity	Stock option activity Options Weighted Weighted Outstanding, April 30, 2021 41,333 $ 79.97 $ 79.97 Issued 1,000 23.10 23.10 Forfeited – – – Exercised – – – Outstanding, July 31, 2021 42,333 $ 78.63 $ 78.63 Exercisable, July 31, 2021 39,833 $ 82.93 $ – Vested and expected to vest 42,333 $ 78.63 $ –
Unvested stock option activity	Unvested stock option activity Options Weighted Unvested, April 30, 2021 4,000 $ 10.05 Granted 1,000 23.10 Vested (2,500 ) – Forfeited – – Unvested, July 31, 2021 2,500 $ 10.05
Schedule of options by exercise price	Schedule of options by exercise price Exercise Price Number of Weighted Weighted Number of Weighted Average $ 156.00 6,967 0.39 $ 156.00 6,967 $ 156.00 $ 87.00 1,634 0.69 $ 87.00 1,634 $ 87.00 $ 110.10 800 0.75 $ 110.10 800 $ 110.10 $ 109.35 1,200 0.94 $ 109.35 1,200 $ 109.35 $ 133.50 800 0.96 $ 133.50 800 $ 133.50 $ 82.95 333 0.60 $ 82.95 333 $ 82.95 $ 83.70 6,000 0.85 $ 83.70 6,000 $ 83.70 $ 80.10 800 2.10 $ 80.10 800 $ 80.10 $ 80.85 667 0.88 $ 80.85 667 $ 80.85 $ 102.45 333 0.96 $ 102.45 333 $ 102.45 $ 97.35 333 1.10 $ 97.35 333 $ 97.35 $ 74.25 6,000 1.58 $ 74.25 6,000 $ 74.25 $ 57.00 800 3.15 $ 57.00 800 $ 57.00 $ 60.60 667 1.38 $ 60.60 667 $ 60.60 $ 55.50 333 1.46 $ 55.50 333 $ 55.50 $ 51.00 333 1.6 $ 51.00 333 $ 51.00 $ 61.20 6,000 2.06 $ 61.20 6,000 $ 61.20 $ 36.00 667 1.88 $ 36.00 667 $ 36.00 $ 37.05 333 1.96 $ 37.05 333 $ 37.05 $ 15.75 333 2.10 $ 15.70 333 $ 15.70 $ 10.05 6,000 2.65 $ 10.05 3,500 $ 10.05 $ 26.55 667 2.38 $ 26.55 667 $ 26.55 $ 16.20 333 2.46 $ 16.20 333 $ 16.20 Total 42,333 1.44 $ 78.63 39,833 $ 82.93
Warrant activity	Warrant activity Warrants Weighted Per Share Outstanding, April 30, 2021 2,981 $ 58.70 Issued – – Exercised – – Expired – – Outstanding, July 31, 2021 2,981 – Exercisable, July 31, 2021 2,981 $ 58.70
Schedule of warrants outstanding and exercisable	Schedule of warrants outstanding and exercisable Exercise Prices Number of Weighted Weighted $97.50 513 0.39 $86.25 580 0.68 $37.50 1,333 0.99 $45.00 555 0.81 2,981 0.79 $ 58.70

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	3 Months Ended
	Jul. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Schedule of future minimum rental payments for operating leases	Schedule of future minimum rental payments for operating leases Period Ending April 30, 2022 Amount $ 8,673 $ 8,673

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	3 Months Ended
	Jul. 31, 2021
Earnings Per Share [Abstract]
Earnings per share calculations	Earnings per share calculations Three months Ended July 31, 2021 2020 Net loss $ (1,025,418 ) $ (883,944 ) Basic weighted average number of shares outstanding 1,591,306 1,119,048 Diluted weighted average number of shares outstanding 1,591,306 1,119,048 Basic and diluted loss per share $ (0.64 ) $ (0.79 )
Schedule of potentially dilutive securities	Schedule of potentially dilutive securities Three months Ended July 31, 2021 2020 Excluded options 42,333 45,800 Excluded warrants 2,981 39,549 Total excluded options and warrants 45,314 85,349

NATURE OF BUSINESS (Details Nar

NATURE OF BUSINESS (Details Narrative) - $ / shares	3 Months Ended
	Jul. 31, 2021	Jul. 12, 2021	Jul. 11, 2021	Apr. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Stockholders' Equity, Reverse Stock Split	1-for-1,500
Common Stock, Shares Authorized	33,333,334	33,333,334	50,000,000,000	33,333,334
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001		$ 0.0001

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	Aug. 19, 2021	Aug. 09, 2021	Jul. 31, 2021	Jul. 31, 2020	Sep. 13, 2021	Apr. 30, 2021	Apr. 30, 2020
Indefinite-lived Intangible Assets [Line Items]
Intangible assets			$ 3,549,427			$ 3,549,427
Impairment of intangible assets			0	$ 0
Research and development costs			143,613	270,574
Uninsured cash balances			679,000			1,921,000
Retained Earnings (Accumulated Deficit)			108,434,913			107,409,495
Net Income (Loss) Attributable to Parent			1,025,418	883,944
Cash			959,270	$ 2,166,596		$ 2,202,106	$ 894,861
Subsequent Event [Member]
Indefinite-lived Intangible Assets [Line Items]
Proceeds from Issuance or Sale of Equity	$ 70,000,000	$ 15,000,000
Cash					$ 88,000,000
Cell In A Box [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible assets			1,549,427
Diabetes License [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible assets			$ 2,000,000
S G Austria [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage investment in SG Austria			14.50%

ACCRUED EXPENSES (Details)

ACCRUED EXPENSES (Details) - USD ($)	Jul. 31, 2021	Apr. 30, 2021
Payables and Accruals [Abstract]
Payroll related costs	$ 509,793	$ 490,904
Director and Officer insurance	12,786	50,805
Other	7,620	10,808
Total	$ 530,199	$ 552,517

ACCRUED EXPENSES (Details Narra

ACCRUED EXPENSES (Details Narrative) - USD ($)	3 Months Ended
	Jul. 31, 2021	Apr. 30, 2021
Liability for Claims and Claims Adjustment Expense [Line Items]
Director and Officer insurance financing	$ 12,786	$ 50,805
D And O Insurance [Member]
Liability for Claims and Claims Adjustment Expense [Line Items]
Policy period	March 8, 2021 through September 8, 2021
Financed interest rate	4.85%
Payment period	eight monthly payments
Payment amount	$ 12,829
Director and Officer insurance financing	$ 12,786	$ 50,805

SMALL BUSINESS ADMINISTRATION_2

SMALL BUSINESS ADMINISTRATION – PAYCHECK PROTECTION PROGRAM (Details Narrative) - USD ($)	1 Months Ended
	Apr. 28, 2021	Mar. 27, 2020
Debt Disclosure [Abstract]
Face amount		$ 75,200
Notes payable maturity date		Apr. 15, 2022
Interest rate		1.00%
Forgiveness of debt	$ 75,200
Accrued interest	$ 779

COMMON STOCK TRANSACTIONS (Deta

COMMON STOCK TRANSACTIONS (Details - Nonvested Option activity) - Restricted Stock [Member]	3 Months Ended
	Jul. 31, 2021$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning balance | shares	2,933
Beginning balance | $ / shares	$ 10.05
Granted | shares	1,336
Granted | $ / shares	$ 23.96
Vested | shares	(2,185)
Vested | $ / shares	$ 16.66
Forfeited | shares	0
Forfeited | $ / shares
Ending balance | shares	2,084
Ending balance | $ / shares	$ 12.03

COMMON STOCK TRANSACTIONS (De_2

COMMON STOCK TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended		12 Months Ended
	Jul. 31, 2021	Jul. 31, 2020	Apr. 30, 2020	Apr. 30, 2021
Shelf Offering [Member]
Class of Stock [Line Items]
Stock issued new, shares	0	156,000
Proceeds from sale of equity	$ 0	$ 1,900,000
Common Stock [Member] | Stock based compensation - options | Director Letter Agreement [Member]
Class of Stock [Line Items]
Stock issued for compensation, shares			1,333
Stock based compensation expense	$ 0	$ 7,356
Unvested shares	0			0
Common Stock [Member] | Officers [Member] | Compensation Agrmt 2020 [Member]
Class of Stock [Line Items]
Stock issued for compensation, shares		4,400
Stock based compensation expense	$ 0	$ 67,320
Unvested shares	0			1,833
Common Stock [Member] | Officers [Member] | Compensation Agrmt 2021 [Member]
Class of Stock [Line Items]
Stock issued for compensation, shares	4,400
Stock based compensation expense	$ 11,055
Unvested shares	1,833
Common Stock [Member] | Nonemployee Members [Member] | Director Letter Agreement [Member]
Class of Stock [Line Items]
Stock issued for compensation, shares		1,000
Stock based compensation expense	$ 3,371	$ 7,029
Unvested shares	0	0
Common Stock [Member] | Four Consultants [Member] | Consulting Agreements [Member]
Class of Stock [Line Items]
Stock issued for compensation, shares		667
Stock based compensation expense	$ 0	$ 4,199
Unvested shares	0			500
Common Stock [Member] | A Consultant [Member] | Medical And Scientific Advisory Board [Member]
Class of Stock [Line Items]
Stock issued for compensation, shares	333
Stock based compensation expense	$ 2,125	$ 0
Unvested shares	0
Common Stock [Member] | Three Nonemployee Member [Member] | Director Letter Agreement [Member]
Class of Stock [Line Items]
Stock issued for compensation, shares	1,002
Stock based compensation expense	$ 4,885
Unvested shares	0
Common Stock [Member] | Two Consultants [Member] | Consulting Agreements [Member]
Class of Stock [Line Items]
Stock issued for compensation, shares	334
Stock based compensation expense	$ 1,620
Unvested shares	251

STOCK OPTIONS AND WARRANTS (Det

STOCK OPTIONS AND WARRANTS (Details - Option Assumptions) - Employee Options [Member]	3 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	0.87%	0.30%
Expected volatility	113.00%	91.00%
Expected lives (years)	2 years 6 months	2 years 6 months
Expected dividend yield	0.00%	0.00%

STOCK OPTIONS AND WARRANTS (D_2

STOCK OPTIONS AND WARRANTS (Details - Option activity) - Equity Option [Member]	3 Months Ended
	Jul. 31, 2021$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning balance | shares	41,333
Beginning balance	$ 79.97
Beginning balance	$ 79.97
Granted | shares	1,000
Granted	$ 23.10
Granted	$ 23.10
Forfeited | shares	0
Forfeited
Forfeited
Exercised | shares	0
Exercised
Exercised
Ending balance | shares	42,333
Ending balance	$ 78.63
Ending balance	$ 78.63
Exercisable | shares	39,833
Exercisable	$ 82.93
Vested and expected to vest | shares	42,333
Vested and expected to vest	$ 78.63

STOCK OPTIONS AND WARRANTS (D_3

STOCK OPTIONS AND WARRANTS (Details - Unvested Option activity) - Unvested Stock Options [Member]	3 Months Ended
	Jul. 31, 2021$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning balance | shares	4,000
Beginning balance | $ / shares	$ 10.05
Granted | shares	1,000
Granted | $ / shares	$ 23.10
Vested | shares	(2,500)
Vested | $ / shares
Forfeited | shares	0
Forfeited | $ / shares
Ending balance | shares	2,500
Ending balance | $ / shares	$ 10.05

STOCK OPTIONS AND WARRANTS (D_4

STOCK OPTIONS AND WARRANTS (Details - Options by exercise price) - $ / shares	3 Months Ended
	Jul. 31, 2021	Apr. 30, 2021
Equity Option [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options	42,333	41,333
Weighted Average Remaining Contractual LIfe (years)	1 year 5 months 8 days
Weighted Average Exercisable Price	$ 78.63	$ 79.97
Numer of Options Exercisable	39,833
$156.00 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options	6,967
Weighted Average Remaining Contractual LIfe (years)	4 months 20 days
Weighted Average Exercisable Price	$ 156
Numer of Options Exercisable	6,967
$87.00 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options	1,634
Weighted Average Remaining Contractual LIfe (years)	8 months 8 days
Weighted Average Exercisable Price	$ 87
Numer of Options Exercisable	1,634
$110.10 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options	800
Weighted Average Remaining Contractual LIfe (years)	9 months
Weighted Average Exercisable Price	$ 110.10
Numer of Options Exercisable	800
$109.35 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options	1,200
Weighted Average Remaining Contractual LIfe (years)	11 months 8 days
Weighted Average Exercisable Price	$ 109.35
Numer of Options Exercisable	1,200
$133.50 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options	800
Weighted Average Remaining Contractual LIfe (years)	11 months 15 days
Weighted Average Exercisable Price	$ 133.50
Numer of Options Exercisable	800
$82.95 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options	333
Weighted Average Remaining Contractual LIfe (years)	7 months 6 days
Weighted Average Exercisable Price	$ 82.95
Numer of Options Exercisable	333
$83.70 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options	6,000
Weighted Average Remaining Contractual LIfe (years)	10 months 6 days
Weighted Average Exercisable Price	$ 83.70
Numer of Options Exercisable	6,000
$80.10 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options	800
Weighted Average Remaining Contractual LIfe (years)	2 years 1 month 6 days
Weighted Average Exercisable Price	$ 80.10
Numer of Options Exercisable	800
$80.85 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options	667
Weighted Average Remaining Contractual LIfe (years)	10 months 17 days
Weighted Average Exercisable Price	$ 80.85
Numer of Options Exercisable	667
$102.45 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options	333
Weighted Average Remaining Contractual LIfe (years)	11 months 15 days
Weighted Average Exercisable Price	$ 102.45
Numer of Options Exercisable	333
$97.35 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options	333
Weighted Average Remaining Contractual LIfe (years)	1 year 1 month 6 days
Weighted Average Exercisable Price	$ 97.35
Numer of Options Exercisable	333
$74.25 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options	6,000
Weighted Average Remaining Contractual LIfe (years)	1 year 6 months 29 days
Weighted Average Exercisable Price	$ 74.25
Numer of Options Exercisable	6,000
$57.00 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options	800
Weighted Average Remaining Contractual LIfe (years)	3 years 1 month 24 days
Weighted Average Exercisable Price	$ 57
Numer of Options Exercisable	800
$60.60 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options	667
Weighted Average Remaining Contractual LIfe (years)	1 year 4 months 17 days
Weighted Average Exercisable Price	$ 60.60
Numer of Options Exercisable	667
$55.50 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options	333
Weighted Average Remaining Contractual LIfe (years)	1 year 5 months 15 days
Weighted Average Exercisable Price	$ 55.50
Numer of Options Exercisable	333
$51.00 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options	333
Weighted Average Remaining Contractual LIfe (years)	1 year 7 months 6 days
Weighted Average Exercisable Price	$ 51
Numer of Options Exercisable	333
$61.20 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options	6,000
Weighted Average Remaining Contractual LIfe (years)	2 years 21 days
Weighted Average Exercisable Price	$ 61.20
Numer of Options Exercisable	6,000
$36.00 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options	667
Weighted Average Remaining Contractual LIfe (years)	1 year 10 months 17 days
Weighted Average Exercisable Price	$ 36
Numer of Options Exercisable	667
$37.05 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options	333
Weighted Average Remaining Contractual LIfe (years)	1 year 11 months 15 days
Weighted Average Exercisable Price	$ 37.05
Numer of Options Exercisable	333
$15.75 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options	333
Weighted Average Remaining Contractual LIfe (years)	2 years 1 month 6 days
Weighted Average Exercisable Price	$ 15.70
Numer of Options Exercisable	333
$10.05 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options	6,000
Weighted Average Remaining Contractual LIfe (years)	2 years 7 months 24 days
Weighted Average Exercisable Price	$ 10.05
Numer of Options Exercisable	3,500
$26.55 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options	667
Weighted Average Remaining Contractual LIfe (years)	2 years 4 months 17 days
Weighted Average Exercisable Price	$ 26.55
Numer of Options Exercisable	667
$16.20 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options	333
Weighted Average Remaining Contractual LIfe (years)	2 years 5 months 15 days
Weighted Average Exercisable Price	$ 16.20
Numer of Options Exercisable	333

STOCK OPTIONS AND WARRANTS (D_5

STOCK OPTIONS AND WARRANTS (Details - Warrant activity) - Warrant [Member]	3 Months Ended
	Jul. 31, 2021$ / sharesshares
Summary of Investment Holdings [Line Items]
Warrants outstanding, beginning balance | shares	2,981
Weighted average exercise price warrants outstanding, beginning balance | $ / shares	$ 58.70
Warrants issued | shares	0
Weighted average exercise price warrants issued | $ / shares
Warrant exercised | shares	0
Weighted average exercise price warrants Exercised | $ / shares
Warrants expired | shares	0
Weighted average exercise price warrants Expired | $ / shares
Warrants outstanding, ending balance | shares	2,981
Weighted average exercise price warrants outstanding, ending balance | $ / shares
Warrants exercisable | shares	2,981
Weighted average exercise price warrants exercisable | $ / shares	$ 58.70

STOCK OPTIONS AND WARRANTS (D_6

STOCK OPTIONS AND WARRANTS (Details - Warrants by exercise price)	3 Months Ended
	Jul. 31, 2021$ / sharesshares
$97.50 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Warrants exercisable	513
Weighted Average Remaining Contractual Life (Years)	4 months 20 days
$86.25 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Warrants exercisable	580
Weighted Average Remaining Contractual Life (Years)	8 months 4 days
$37.50 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Warrants exercisable	1,333
Weighted Average Remaining Contractual Life (Years)	11 months 26 days
$45.00 [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Warrants exercisable	555
Weighted Average Remaining Contractual Life (Years)	9 months 21 days
Warrant [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Warrants exercisable	2,981
Weighted Average Remaining Contractual Life (Years)	9 months 14 days
Weighted average exercise price exercisable | $ / shares	$ 58.70

STOCK OPTIONS AND WARRANTS (D_7

STOCK OPTIONS AND WARRANTS (Details Narrative) - USD ($)	3 Months Ended
	Jul. 31, 2021	Jul. 31, 2020	Apr. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 11,055	$ 67,320
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition	5 months
Stock price per share	$ 12.01
Equity Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding	42,333		41,333
Options granted in period	1,000
Aggregate intrinsic value	$ 6,860
Equity Option [Member] | Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted in period	1,000	1,000
Stock-based compensation	$ 24,144	$ 72,317
Unrecognized compensation expense	$ 15,976
Equity Option [Member] | $0.18 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted in period	0	0
Non Employee Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation	$ 0	$ 0

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
S G Austria [Member]
Related Party Transaction [Line Items]
Purchases from related parties	$ 58,000	$ 64,000
Vin De Bona [Member]
Related Party Transaction [Line Items]
Consulting fees	32,000	23,000
Share base compensation expense	$ 0	$ 8,000
Vin De Bona [Member] | Salmons [Member]
Related Party Transaction [Line Items]
Stock issued for services, shares	0	167
S G Austria [Member]
Related Party Transaction [Line Items]
Equity interest owned	14.50%

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details)	Jul. 31, 2021USD ($)
Commitments and Contingencies Disclosure [Abstract]
Minimum operating lease expense 2022	$ 8,673
Minimum operating lease expense	$ 8,673

COMMITMENTS AND CONTINGENCIES_3

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	3 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Rent and lease expense	$ 3,738	$ 7,152

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	3 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Income Tax Disclosure [Abstract]
Income tax expense	$ 0	$ 0
Increase in valuation allowance	295,000	98,000
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued	$ 0	$ 0

EARNINGS PER SHARE (Details - p

EARNINGS PER SHARE (Details - per share calculation) - USD ($)	3 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Earnings Per Share [Abstract]
Net loss	$ (1,025,418)	$ (883,944)
Basic weighted average number of shares outstanding	1,591,306	1,119,048
Diluted weighted average number of shares outstanding	1,591,306	1,119,048
Basic and diluted loss per share	$ (0.64)	$ (0.79)

EARNINGS PER SHARE (Details - d

EARNINGS PER SHARE (Details - diluted shares) - shares	3 Months Ended
	Jul. 31, 2021	Jul. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	45,314	85,349
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	42,333	45,800
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	2,981	39,549